TargetBeta
TGFB1
transforming growth factor beta 1 · also CED, TGFbeta, TGFB, DPD1 · Transforming growth factor beta family
7 programs in company-led studies act on TGFB1, from 7 companies: 4 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 206 running | CD274 | NCIt |
| Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890rule | Incyte | phase 3 | 33 running | PDCD1 | NCIt |
| ficerafusp alfarule | Bicara Therapeutics | phase 3 | 33 running | EGFR | NCIt |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 42 running | PDCD1 | the company's pipeline |
| Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18rule | Suzhou Zelgen Biopharmaceuticals | phase 2 | 22 running | VEGFA | NCIt |
| Autologous Priming Antigen-inducible Anti-PSMA CAR T-cells AB-3028rule | Arsenal Biosciences | phase 2 | 10 running | FAS, FOLH1, TGFBR2 | NCIt |
| Anti-GARP Monoclonal Antibody PBA-0111rule | Pure Biologics | early phase 1 | 11 running | LRRC32 | NCIt |
Conditions their studies are in
- Pancreatic Neoplasms, 2 programs
- Squamous Cell Carcinoma of Head and Neck, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Colorectal Neoplasms, 1 program
- Nasopharyngeal Carcinoma, 1 program
- Neoplasm Metastasis, 1 program
- Prostatic Neoplasms, 1 program
- Stomach Neoplasms, 1 program
- Uterine Cervical Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 · Sino Biopharmaceutical · phase 3 · NCT06767813
- May 2027Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18 · Suzhou Zelgen Biopharmaceuticals · phase 2 · NCT06938880
- Jul 30, 2027retlirafusp alfa · Jiangsu HengRui Medicine · phase 3 · NCT05503888
- Oct 31, 2027ficerafusp alfa · Bicara Therapeutics · phase 3 · NCT04429542
- Dec 29, 2028Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 · Incyte · phase 3 · NCT07284849
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.